Fig. 1

DTX2 is highly expressed and predicts poor prognosis in glioma samples. A Differences in mRNA levels of DTX2 in 33 cancer and paraneoplastic tissues from TCGA. B Differential expression of DTX2 between normal tissues from the Genotype-Tissue Expression (GTEx) database and cancer tissues from TCGA. C, D Differential expression of DTX2 in LGG (C) and glioblastoma (GBM) (D) was further analyzed in combination with normal brain tissue data from the GTEx database. Blue and red represent normal and tumor tissues, respectively. E DTX2 exhibited favorable prognostic value within the glioma cohort, particularly concerning OS, DSS, and PFI patterns. (Low: median =  < 50%; High: median > 50%). F AUC values of time-dependent ROC curves for the past decade. G Kaplan–Meier survival plots for glioma patients with high and low DTX2 expression from HPA. (Low: negative and weak staining; High: median and strong staining). H IHC staining to investigate the expression of DTX2 in clinical glioma tissues. I DTX2 protein expression in glioma tissues (n = 3) and controls (n = 3) as detected using western blotting